A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells

Journal of Biological Chemistry

Volumn 290, Issue 6, 2015, Pages 3418-3429

  Xiao, Hui ^a   Bid, Hemant Kumar ^a   Jou, David ^a   Wu, Xiaojuan ^a   Yu, Wenying ^a   Li, Chenglong ^a   Houghton, Peter J ^a   Lin, Jiayuh ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; CELL CULTURE; CELL DEATH; DISEASES; IMMUNOLOGY; PHOSPHORYLATION; RADIATION EFFECTS; SIGNALING;

HUMAN CANCER CELLS; INHIBITORY ACTIVITY; INSULIN-LIKE GROWTH FACTOR; LEUKEMIA INHIBITORY FACTORS; NUCLEAR LOCALIZATION; NUCLEAR TRANSLOCATIONS; SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTIONS; SIGNALING PATHWAYS;

CELL SIGNALING;

5,8 DIOXO 6 (PYRIDIN 3 YLAMINO) 5,8 DIHYDRONAPHTHALENE 1 SULFONAMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MICRORNA 21; PROTEIN BCL XL; SOMATOMEDIN B; SOMATOMEDIN C; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; 5,8-DIOXO-6-(PYRIDIN-3-YLAMINO)-5,8-DIHYDRONAPHTHALENE-1-SULFONAMIDE; AMINOPYRIDINE DERIVATIVE; BIRC5 PROTEIN, HUMAN; CYCLIN D; CYTOKINE; INHIBITOR OF APOPTOSIS PROTEIN; MICRORNA; MIRN21 MICRORNA, HUMAN; PROTEIN BCL X; SIGNAL PEPTIDE; SULFONAMIDE;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL MIGRATION; CELL NUCLEUS; CELL VIABILITY; DOWN REGULATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; MONOTHERAPY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; ACTIVE TRANSPORT; ANGIOGENESIS; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; SYNTHESIS; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CELL SURVIVAL; CISPLATIN; CYCLIN D; CYTOKINES; DOWN-REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEDULLOBLASTOMA; MICRORNAS; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SULFONAMIDES;

EID: 84922440337     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.616748     Document Type: Article

References (69)

1. Barton, B. E., Karras, J. G., Murphy, T. F., Barton, A., and Huang, H. F. (2004) Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol. Cancer Ther. 3, 11-20
2. Turkson, J., and Jove, R. (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19, 6613-6626
3. Song, H., Wang, R., Wang, S., and Lin, J. (2005) A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 102, 4700-4705
4. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421
5. Zhong, Z., Wen, Z., and Darnell, J. E., Jr. (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95-98
6. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., and Darnell, J. E., Jr. (1999) Stat3 as an oncogene. Cell 98, 295-303
7. Schlessinger, K., and Levy, D. E. (2005) Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res. 65, 5828-5834
8. Calò, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N., and Russo, A. (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell Physiol. 197, 157-168
9. Clark, J., Edwards, S., Feber, A., Flohr, P., John, M., Giddings, I., Crossland, S., Stratton, M. R., Wooster, R., Campbell, C., and Cooper, C. S. (2003) Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 22, 1247-1252
10. Zong, C. S., Zeng, L., Jiang, Y., Sadowski, H. B., and Wang, L. H. (1998) Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J. Biol. Chem. 273, 28065-28072
11. Kuropatwinski, K. K., De Imus, C., Gearing, D., Baumann, H., and Mosley, B. (1997) Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6. J. Biol. Chem. 272, 15135-15144
12. Cressman, D. E., Greenbaum, L. E., De Angelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., and Taub, R. (1996) Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274, 1379-1383
13. Darnell, J. E., Jr. (1997) STATs and gene regulation. Science 277, 1630-1635
14. Bromberg, J., and Darnell, J. E., Jr. (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19, 2468-2473
15. Turkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z., Haura, E., Laudano, A., Sebti, S., Hamilton, A. D., and Jove, R. (2001) Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276, 45443-45455
16. Aoki, Y., Feldman, G. M., and Tosato, G. (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101, 1535-1542
17. Xu, Q., Briggs, J., Park, S., Niu, G., Kortylewski, M., Zhang, S., Gritsko, T., Turkson, J., Kay, H., Semenza, G. L., Cheng, J. Q., Jove, R., and Yu, H. (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24, 5552-5560
18. Amin, H. M., McDonnell, T. J., Ma, Y., Lin, Q., Fujio, Y., Kunisada, K., Leventaki, V., Das, P., Rassidakis, G. Z., Cutler, C., Medeiros, L. J., and Lai, R. (2004) Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 23, 5426-5434
19. Bollrath, J., Phesse, T. J., Von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, O., Schwitalla, S., Matthews, V., Schmid, R. M., Kirchner, T., Arkan, M. C., Ernst, M., and Greten, F. R. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91-102
20. Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., and Jove, R. (1998) Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18, 2545-2552
21. Bowman, T., Garcia, R., Turkson, J., and Jove, R. (2000) STATs in oncogenesis. Oncogene 19, 2474-2488
22. Yu, C. L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., and Jove, R. (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269, 81-83
23. Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., Dalton, W., Jove, R., Pardoll, D., and Yu, H. (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10, 48-54
24. Yu, H., Pardoll, D., and Jove, R. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809
25. Fu, X. Y. (2006) STAT3 in immune responses and inflammatory bowel diseases. Cell Res. 16, 214-219
26. Hodge, D. R, Hurt, E. M., and Farrar, W. L. (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41, 2502-2512
27. Yu, H., Kortylewski, M., and Pardoll, D. (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41-51
28. Wei, D., Le, X., Zheng, L., Wang, L., Frey, J. A., Gao, A. C., Peng, Z., Huang, S., Xiong, H. Q., Abbruzzese, J. L., and Xie, K. (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22, 319-329
29. Dechow, T. N., Pedranzini, L., Leitch, A., Leslie, K., Gerald, W. L., Linkov, I., and Bromberg, J. F. (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl. Acad. Sci. U. S. A. 101, 10602-10607
30. Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., Heller, R., Ellis, L. M., Karras, J., Bromberg, J., Pardoll, D., Jove, R., and Yu, H. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000-2008
31. Jones, D. T., Jäger, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y. J., Pugh, T. J., Hovestadt, V., Stütz, A. M., Rausch, T., Warnatz, H. J., Ryzhova, M., Bender, S., Sturm, D., Pleier, S., Cin, H., Pfaff, E., Sieber, L., Wittmann, A., Remke, M., Witt, H., Hutter, S., Tzaridis, T., Weischenfeldt, J., Raeder, B., Avci, M., Amstislavskiy, V., Zapatka, M., Weber, U. D., Wang, Q., Lasitschka, B., Bartholomae, C. C., Schmidt, M., Von Kalle, C., Ast, V., Lawerenz, C., Eils, J., Kabbe, R., Benes, V., Van Sluis, P., Koster, J., Volckmann, R., Shih, D., Betts, M. J., Russell, R. B., Coco, S., Tonini, G. P., Schüller, U., Hans, V., Graf, N., Kim, Y. J., Monoranu, C., Roggendorf, W., Unterberg, A., Herold-Mende, C., Milde, T., Kulozik, A. E., Von Deimling, A., Witt, O., Maass, E., Rossler, J., Ebinger, M., Schuhmann, M. U., Fruhwald, M. C., Hasselblatt, M., Jabado, N., Rutkowski, S., Von Bueren, A. O., Williamson, D., Clifford, S. C., McCabe, M. G., Collins, V. P., Wolf, S., Wiemann, S., Lehrach, H., Brors, B., Scheurlen, W., Felsberg, J., Reifenberger, G., Northcott, P. A., Taylor, M. D., Meyerson, M., Pomeroy, S. L., Yaspo, M. L., Korbel, J. O., Korshunov, A., Eils, R., Pfister, S. M., and Lichter, P. (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 100-105
32. Ling, X., and Arlinghaus, R. B. (2005) Knockdown of STAT3 expression by RNAinterference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res. 65, 2532-2536
33. Yang, F., Jove, V., Xin, H., Hedvat, M., Van Meter, T. E., and Yu, H. (2010) Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol. Cancer Res. 8, 35-45
34. Burke, W. M., Jin, X., Lin, H. J., Huang, M., Liu, R., Reynolds, R. K., and Lin, J. (2001) Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20, 7925-7934
35. Yu, H., and Jove, R. (2004) The STATs of cancer: new molecular targets come of age. Nat. Rev. Cancer 4, 97-105
36. Yu, W., Xiao, H., Lin, J., and Li, C. (2013) Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J. Med. Chem. 56, 4402-4412
37. Huey, R., Morris, G. M., Olson, A. J., and Goodsell, D. S. (2007) A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 28, 1145-1152
38. Tian, X., Li, J., Ma, Z. M., Zhao, C., Wan, D. F., and Wen, Y. M. (2009) Role of hepatitis B surface antigen in the development of hepatocellular carcinoma: regulation of lymphoid enhancer-binding factor 1. J. Exp. Clin. Cancer Res. 28, 58
39. Paydas, S., Tanriverdi, K., Yavuz, S., Disel, U., Sahin, B., and Burgut, R. (2003) Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Ann. Oncol. 14, 1045-1050
40. Shimonovitz, S., Hurwitz, A., Dushnik, M., Anteby, E., Geva-Eldar, T., and Yagel, S. (1994) Developmental regulation of the expression of 72 and 92 kDa type IV collagenases in human trophoblasts: a possible mechanism for control of trophoblast invasion. Am. J. Obstet. Gynecol. 171, 832-838
41. Yamaguchi, H., Inokuchi, K., Tarusawa, M., and Dan, K. (2002) Mutation of bcl-x gene in non-Hodgkin's lymphoma. Am. J. Hematol. 69, 74-76
42. Thaloor, D., Singh, A. K., Sidhu, G. S., Prasad, P. V., Kleinman, H. K., and Maheshwari, R. K. (1998) Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ. 9, 305-312
43. Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., Beraldi, E., Bazov, J., Fazli, L., Chi, K., Gleave, M., and Zoubeidi, A. (2013) Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res. 73, 3109-3119
44. Dong, S., Cheng, Y., Yang, J., Li, J., Liu, X., Wang, X., Wang, D., Krall, T. J., Delphin, E. S., and Zhang, C. (2009) MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J. Biol. Chem. 284, 29514-29525
45. Grunder, E., D'Ambrosio, R., Fiaschetti, G., Abela, L., Arcaro, A., Zuzak, T., Ohgaki, H., Lv, S. Q., Shalaby, T., and Grotzer, M. (2011) MicroRNA-21 suppression impedes medulloblastoma cell migration. Eur. J. Cancer 47, 2479-2490
46. Connolly, E., Melegari, M., Landgraf, P., Tchaikovskaya, T., Tennant, B. C., Slagle, B. L., Rogler, L. E., Zavolan, M., Tuschl, T., and Rogler, C. E. (2008) Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirusassociated hepatocellular carcinoma contributes to the malignant phenotype. Am. J. Pathol. 173, 856-864
47. Iliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L., and Struhl, K. (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 39, 493-506
48. Liu, Y., Li, P. K., Li, C., and Lin, J. (2010) Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J. Biol. Chem. 285, 27429-27439
49. Cheng, J. G., Chen, J. R., Hernandez, L., Alvord, W. G., and Stewart, C. L. (2001) Dual control of LIF expression and LIF receptor function regulate Stat3 activation at the onset of uterine receptivity and embryo implantation. Proc. Natl. Acad. Sci. U. S. A. 98, 8680-8685
50. Vogel, S., Wottawa, M., Farhat, K., Zieseniss, A., Schnelle, M., Le-Huu, S., Von Ahlen, M., Malz, C., Camenisch, G., and Katschinski, D. M. (2010) Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent cofilin phosphorylation. J. Biol. Chem. 285, 33756-33763
51. Badr, G., Mohany, M., and Abu-Tarboush, F. (2011) Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression. Lipids Health Dis. 10, 236
52. Osugi, T., Oshima, Y., Fujio, Y., Funamoto, M., Yamashita, A., Negoro, S., Kunisada, K., Izumi, M., Nakaoka, Y., Hirota, H., Okabe, M., Yamauchi-Takihara, K., Kawase, I., and Kishimoto, T. (2002) Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J. Biol. Chem. 277, 6676-6681
53. Wang, L., Luo, J., and He, S. (2007) Induction of MMP-9 release from human dermal fibroblasts by thrombin: involvement of JAK/STAT3 signaling pathway in MMP-9 release. BMC Cell Biol. 8, 14
54. Huang, S., Chen, M., Shen, Y., Shen, W., Guo, H., Gao, Q., and Zou, X. (2012) Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett. 315, 198-205
55. Kato, K., Nomoto, M., Izumi, H., Ise, T., Nakano, S., Niho, Y., and Kohno, K. (2000) Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the up-regulation in cisplatin-resistant cells. Biochim. Biophys. Acta 1493, 91-100
56. Real, P. J., Sierra, A., De Juan, A., Segovia, J. C., Lopez-Vega, J. M., and Fernandez-Luna, J. L. (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21, 7611-7618
57. Shen, Y., Devgan, G., Darnell, J. E., Jr., and Bromberg, J. F. (2001) Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc. Natl. Acad. Sci. U. S. A. 98, 1543-1548
58. Rebbaa, A., Chou, P. M., and Mirkin, B. L. (2001) Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol. Med. 7, 393-400
59. Alas, S., and Bonavida, B. (2003) Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin. Cancer Res. 9, 316-326
60. Packer, R. J., Cogen, P., Vezina, G., and Rorke, L. B. (1999) Medulloblastoma: clinical and biologic aspects. Neuro-oncology 1, 232-250
61. Packer, R. J., Gajjar, A., Vezina, G., Rorke-Adams, L., Burger, P. C., Robertson, P. L., Bayer, L., La Fond, D., Donahue, B. R., Marymont, M. H., Muraszko, K., Langston, J., and Sposto, R. (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol. 24, 4202-4208
62. Rossi, A., Caracciolo, V., Russo, G., Reiss, K., and Giordano, A. (2008) Medulloblastoma: from molecular pathology to therapy. Clin. Cancer Res. 14, 971-976
63. Buettner, R., Mora, L. B., and Jove, R. (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8, 945-954
64. Inghirami, G., Chiarle, R., Simmons, W. J., Piva, R., Schlessinger, K., and Levy, D. E. (2005) New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 4, 1131-1133
65. Chiarle, R., Simmons, W. J., Cai, H., Dhall, G., Zamo, A., Raz, R., Karras, J. G., Levy, D. E., and Inghirami, G. (2005) Stat3 is required for ALKmediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11, 623-629
66. Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L., Jove, R., McLaughlin, M. M., Lawrence, N. J., Sebti, S. M., and Turkson, J. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 104, 7391-7396
67. Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., and Turkson, J. (2010) A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem. Pharmacol. 79, 1398-1409
68. Zhang, X., Yue, P., Page, B. D., Li, T., Zhao, W., Namanja, A. T., Paladino, D., Zhao, J., Chen, Y., Gunning, P. T., and Turkson, J. (2012) Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc. Natl. Acad. Sci. U. S. A. 109, 9623-9628
69. Miklossy, G., Hilliard, T. S., and Turkson, J. (2013) Therapeutic modulators of STAT signalling for human diseases. Nat. Rev. Drug Discov. 12, 611-629